Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of REGN727 in autosomal dominant hypercholesterolemia with PCSK9 gain-of-function mutations
2011-004308-39Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alirocumab in familial hypercholesterolemia (FH) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary: percent change in direct serum LDL cholesterol. Started Feb 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2011-004308-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004308-39.